Abstract:
Atropine is currently the most effective therapy for myopia control. Recent clinical trials
demonstrated low-dose atropine eye drops such as 0.01% resulted in retardation of myopia
progression, with less side effects compared to higher concentration preparation. For children aged
6-10 years with myopia of at least 1D and myopia progression of at least 0.50D per year, the WHO
recommends atropine as a potential first line treatment for myopia. Proposed strategies include a
combination of low-dose atropine with increase outdoor time.
We made pilot study and 1-year results suggest that atropine 0.01% eyedrops can slow myopia
progression and axial elongation of the eye.